Overview

Pharmacokinetics and Safety/Tolerability Profiles of DA-5206 Versus Talion® Under Fasting and Fed States in Healthy Male Subjects

Status:
Completed
Trial end date:
2017-06-29
Target enrollment:
Participant gender:
Summary
This is Open-label, Randomized, 3-sequence study to compare of pharmacokinetics and safety/tolerability profiles betweens DA-5206, a SR formulation of bepotastine besilate and Talion®, a IR formulation of bepotastine besilate under fasting and fed states in healthy male subjects
Phase:
Phase 1
Details
Lead Sponsor:
Dong-A ST Co., Ltd.